AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference

  AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference

PR Newswire

REDWOOD CITY, Calif., May 16, 2013

REDWOOD CITY, Calif., May 16, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals,
Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the
development and commercialization of innovative therapies for the treatment of
acute and breakthrough pain, today announced that Richard King, President and
CEO, will present a corporate overview at the UBS Global Healthcare Conference
at the Sheraton New York Hotel in New York, NY. The presentation is scheduled
for Wednesday, May 22, 2013 at 9:30 a.m. ET/6:30 a.m. PT.

The presentation will be webcast live and can be accessed through the
Investors page followed by referring to the Event Calendar page at
www.acelrx.com. For those not available to listen to the live broadcast, a
replay of the presentation will be archived and available through
www.acelrx.com.

About AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on
the development and commercialization of innovative therapies for the
treatment of acute and breakthrough pain. AcelRx's lead product candidate, the
Sufentanil NanoTab PCA System, or NanoTab System, is designed to solve the
problems associated with post-operative intravenous patient-controlled
analgesia which has been shown to cause harm to patients following surgery
because of the side effects of morphine, the invasive IV route of delivery and
the complexity of infusion pumps. AcelRx has announced results from two Phase
3 clinical trials for the NanoTab System, and a third Phase 3 study has
completed enrollment, with data expected in the second quarter of 2013. A New
Drug Application submission is planned for the third quarter of 2013. AcelRx
recently announced positive top-line results for a Phase 2 trial for ARX-04, a
sufentanil formulation for the treatment of moderate-to-severe acute pain,
funded through a grant from USAMRMC. The company has two additional pain
treatment product candidates, ARX-02 and ARX-03, which have completed Phase 2
clinical development. For additional information about AcelRx's clinical
programs, please visit www.acelrx.com.

Forward Looking Statements

This press release contains forward-looking statements, including, but not
limited to, statements related to the release and anticipated timing of
additional NanoTab System clinical trial data, anticipated timing of
completion of AcelRx Pharmaceuticals' current clinical trials, submission of
the NDA, and the therapeutic potential of AcelRx Pharmaceuticals' product
candidates. These forward-looking statements are based on AcelRx
Pharmaceuticals' current expectations and inherently involve significant risks
and uncertainties. AcelRx Pharmaceuticals' actual results and the timing of
events could differ materially from those anticipated in such forward-looking
statements as a result of these risks and uncertainties, which include,
without limitation, risks related to: the success, cost and timing of AcelRx
Pharmaceuticals' product development activities and clinical trials; its
ability to obtain and maintain regulatory approvals of its product candidates;
the market potential for its product candidates; and other risks detailed in
the "Risk Factors" and elsewhere in AcelRx Pharmaceuticals' U.S. Securities
and Exchange Commission filings, including its Quarterly Report on Form 10-Q
filed with the SEC on May 8, 2013. AcelRx Pharmaceuticals undertakes no duty
or obligation to update any forward-looking statements contained in this
release as a result of new information, future events or changes in its
expectations.

(Logo: http://photos.prnewswire.com/prnh/20130226/MM67303LOGO)

SOURCE AcelRx Pharmaceuticals, Inc.

Website: http://www.acelrx.com
Contact: Jim Welch, Chief Financial Officer, 650.216.3511, jwelch@acelrx.com
 
Press spacebar to pause and continue. Press esc to stop.